Monopar Therapeutics Inc. (MNPR)
Market: NASD |
Currency: USD
Address: 1000 Skokie Boulevard
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Show more
📈 Monopar Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$61.25
-
Upside/Downside from Analyst Target:
85.61%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.200000 |
- |
2024-08-13 |
- |
Stock split |
|
Total Amount for 2024: $0.200000 |
📅 Earnings & EPS History for Monopar Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-30 (estimated upcoming) | - |
| 2025-11-06 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-08-07 (estimated upcoming) | - |
| 2025-08-06 (estimated upcoming) | - |
| 2025-05-13 | - |
| 2025-05-09 | - |
| 2025-05-07 | - |
| 2025-05-06 | - |
| 2025-03-31 | -2.75 |
| 2025-03-25 | - |
| 2024-11-08 | -0.37 |
| 2024-08-09 | -0.5 |
| 2024-08-08 | -0.5 |
| 2024-05-09 | -0.1 |
| 2024-05-08 | -0.1 |
| 2024-03-28 | -0.12 |
| 2024-03-27 | -0.12 |
| 2023-11-09 | -0.14 |
| 2023-11-08 | -0.14 |
| 2023-08-10 | -0.16 |
| 2023-08-09 | -0.16 |
| 2023-05-11 | -0.19 |
| 2023-05-10 | -0.19 |
| 2023-03-23 | -0.23 |
| 2023-03-22 | -0.23 |
| 2022-11-10 | -0.19 |
| 2022-11-09 | -0.19 |
| 2022-08-11 | -0.22 |
| 2022-08-10 | -0.22 |
| 2022-05-12 | -0.19 |
| 2022-05-11 | -0.19 |
| 2022-03-24 | -0.21 |
| 2022-03-23 | -0.21 |
| 2021-11-12 | -0.2 |
| 2021-11-11 | -0.2 |
| 2021-08-12 | -0.17 |
| 2021-08-11 | -0.17 |
| 2021-05-13 | -0.16 |
| 2021-05-12 | -0.16 |
| 2021-03-25 | -0.2 |
| 2021-03-24 | -0.2 |
| 2020-11-12 | -0.15 |
| 2020-11-11 | -0.15 |
| 2020-08-06 | -0.14 |
| 2020-08-05 | -0.14 |
| 2020-05-07 | -0.1 |
| 2020-05-06 | -0.1 |
| 2020-03-27 | -0.13 |
| 2020-03-26 | -0.13 |
| 2019-12-22 | - |
📰 Related News & Research
No related articles found for "monopar therapeutics".
